PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference

Company Overview - PolyPid Ltd. is a late-stage biopharma company focused on improving surgical outcomes through locally administered, controlled, prolonged-release therapeutics [2] - The company utilizes its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology to enable precise delivery of drugs at optimal release rates over durations ranging from several days to months [2] Recent Developments - Dalit Hazan, Deputy CEO, will present at the 14th meeting of the Israel Controlled Release Society (ICRS) Conference from September 7-9, 2025 [1] - The presentation will cover the topic "Novel Local Prolonged Drug Delivery: From Platform Idea to a Successful Phase III Trial" on September 7, 2025 [2] Product Pipeline - PolyPid's lead product candidate, D-PLEX₁₀₀, aims to prevent abdominal colorectal surgical site infections, with a New Drug Application (NDA) submission expected in early 2026 following positive phase 3 results [2] - The company also has an innovative pipeline targeting oncology, obesity, and diabetes [2]